NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • NIHR Oxford BRC impact
    • Steering Committee
    • Promoting equality, diversity and inclusion in research
    • Current Vacancies
    • Stay in Touch
    • Contact Us
  • Research

        • Research Overview
        • Clinical Research Facility
        • Health Economics
        • Ethics in the NIHR Oxford BRC
        • Medical Statistics
        • Infections in Oxfordshire Database (IORD)
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient and Public Involvement
    • For patients and the public
    • For researchers
    • More information
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Pre-doctoral Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • PARC Programme
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

** HEALTH RESEARCH SHOWCASE THURSDAY 29 MAY 2025 **

News

You are here: Home > Gene and Cell Therapy > Test developed to identify new-borns at risk of leukaemia

Test developed to identify new-borns at risk of leukaemia

21 August 2020 · Listed under Gene and Cell Therapy, Molecular Diagnostics

Oxford researchers have developed a new method to quickly identify cancerous cells in babies at risk of leukaemia. The team hope that the new protocol could make rapid testing more accessible for clinical laboratories around the globe.

leukaemia blood cells
Leukaemia blood cells

Until now, the only reliable way to know if a baby with Down’s syndrome is at risk of developing leukaemia, an aggressive form of blood cancer, was by a relatively expensive DNA mutational analysis of a blood sample.

Now, in a study published in the journal Blood, groups at the MRC Molecular Haematology Unit (MHU) have shown how they have developed an alternative, cheap method that quickly identifies cancerous cells. 

The groups are led by the Professor Paresh Vyas, the Oxford BRC’s Co-theme Lead for Haematology and Theme Lead for Molecular Diagnostics, and by Prof Irene Roberts, of the University of Oxford’s Department of Paediatrics.

Babies with Down’s syndrome who have an alteration in the GATA1 gene have a remarkable propensity to develop a type of leukaemia known as ML-DS. Thirty percent of babies with Down’s syndrome have acquired mutations in the gene and 10% of them develop ML-DS before the age of five.

An altered GATA1 gene also causes a pre-leukemic disorder known as TAM, which in 20% of cases is fatal. It is important to identify babies with the genetic mutation who are at risk of developing ML-DS or who suffer of TAM to provide the best care possible.

Ideally, babies born with Down’s syndrome are tested at birth for GATA1 mutations by next-generation sequencing methods. Unfortunately, not all hospital laboratories can make use of this method, especially in developing countries, because it requires technical expertise and expensive equipment.

Instead of relying on DNA mutational analysis, the new approach developed by Profs Vyas and Roberts relies on flow cytometry, a method that is available in most haematology hospitals.

Prof Paresh Vyas
Prof Paresh Vyas

The value of this simple method comes from quick and easy identification of GATA1 mutant cells in blood samples from new-born babies.

It is hoped that one day most clinical laboratories around the world could make use of this method when next-generation sequencing methods are not available.

The GATA1 gene encodes two versions of a DNA binding protein important for healthy red blood cell and platelet production. These variants are known as GATA1fl and GATAs. Surprisingly, when mutations occur, they lead to exclusive expression of only GATA1s.

As well as the NIHR Oxford BRC, the research teams were funded by blood cancer charity Bloodwise, the MRC Molecular Haematology Unit, and Lady Tata Memorial Trust.

← BRC researchers’ work recognised with Vice-Chancellor’s Awards
Eight BRC projects get RCF funding →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Feedback

We’d love to hear your feedback. Please contact us at [email protected]

Oxford BRC on Social Media

  • Bluesky
  • Facebook
  • LinkedIn
  • Threads
  • Twitter
  • YouTube
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2025 NIHR Oxford Biomedical Research Centre